Russian Heart Failure Journal 2006year A possibility of using metoprolol succinate in myocardial infarction complicated with heart failure
A possibility of using metoprolol succinate in myocardial infarction complicated with heart failure
Tereshchenko S.N., Kositsyna I.V., Dzhaiani N.A., Golubev A.V.
Urgency. Considering a high prevalence of HF and unfavorable prediction in this group of patients, it is presently urgent to study a possibility of early treatment with β–adrenoblockers (BAB) in acute MI (AMI) complicated with HF. Aim. The study was focused on evaluating a possibility of using metoprolol succinate in patients with AMI complicated with HF. Materials and methods. Study included 61 patients with AMI which had happened within 24 hours. Patients were randomized to two groups: patients of group 1 (n=30) received a starting dose of metoprolol succinate, metoprolol CR/XL (Betaloc ZOK, ASTRA ZENECA) within 24 hours of MI, and patients of group 2 (n=31) received a traditional treatment. A BAB (mainly metoprolol tartrate) was administered after a mean of 2–4 days of MI. Efficacy of the administered therapy was evaluated by the following parameters: clinical course of MI; incidence of postinfarction angina; HF progression; death rate; and time course of echoCG parameters. Results. Early administration of metoprolol CR/XL as a part of multimodality therapy for AMI complicated with HF positively influenced the course of postinfacrtion period due to a considerable decrease in death rate and a beneficial effect on incidence of recurrent MI. Administration of metoprolol CR/XL reduced the incidence of HF development and progression.